United States Health

JBS (NYSE:JBS) reported record second-quarter 2026 net sales of $23.9 billion, up 14% from $21 billion a year earlier.

Jazz Pharmaceuticals (NASDAQ:JAZZ) agreed to acquire privately held Actio Biosciences for $820 million upfront, adding the clinical-stage epilepsy candidate ABS-1230 to its rare neurological disease portfolio.

Village Farms (NASDAQ:VFF) reported Q2 2026 consolidated net sales of $64 million, up 7% year over year, as cannabis revenue reached a record $53.5 million.

Axsome Therapeutics (NASDAQ:AXSM) reported Q2 2026 total net product revenue of $218.4 million, up 46% year over year, led by continued growth from AUVELITY.

BeOne Medicines (NASDAQ:ONC) and Revolution Medicines (NASDAQ:RVMD) announced a multi-part oncology collaboration combining clinical research programs with a regional rights agreement covering four RAS(ON) inhibitors in selected Asian markets.

Dole (NYSE:DOLE) reported Q2 2026 revenue of $2.499 billion, up 2.9%, while net income increased to $35.1 million from $18 million.

National Energy Services Reunited (NASDAQ:NESR) reported Q2 2026 revenue of $520.8 million, up 59.1% year over year, while net income increased to $44.0 million.

Innate Pharma (NASDAQ:IPHA) announced plans to begin the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma, subject to completion of its strategic partnership with Sobi.

Oculis (NASDAQ:OCS) signed an agreement to acquire worldwide development and commercial rights to Privosegtor (ACT-01) from Accure Therapeutics, along with rights to an early-stage neurology candidate known as ACT-02.

ANI Pharmaceuticals (NASDAQ:ANIP) reported record Q2 2026 net revenue of $266.0 million, up 25.9%, while GAAP net income reached $24.7 million.

Claritev (NYSE:CTEV) reported Q2 2026 revenue of $257.5 million, up 6.6%, while its net loss narrowed to $59.2 million from $62.6 million.

Privia Health Group (NASDAQ:PRVA) reported Q2 2026 revenue of $632.6 million, up 21.4%, with net income reaching $9 million.